Corvus制药 CRVS 深 沪
等待开盘 11-07 09:30:00 美东时间
7.82
+0.290
+3.85%
华盛通- 最 高8.05
- 今 开7.60
- 成交量 164.17万股
- 最 低 7.41
- 昨 收 7.53
- 总市值 5.83亿
- 52周最高 9.55
- 市盈率 静 --
- 换手率 2.20%
- 52周最低 2.54
- 委 比 78.48%
- 总股本 7451.40万
- 历史最高 22.137
- 量 比 1.17
- 振 幅 8.50%
- 历史最低 0.607
- 每 手 1
- 风险率 1.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Corvus Pharmaceuticals' leadership team will meet with investors and participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10, 2025. The chat, held at 8:30 am ET, will be webcast live and available for 90 days via the company's investor relations website. Corvus is a clinical-stage biopharmaceutical company developing ITK inhibition for cancer and immune diseases.
10-31 11:30
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development...
10-21 20:05
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Corvus Pharmaceuticals announced interim results from a Phase 1b/2 trial assessing ciforadenant in combination with ipilimumab and nivolumab as a potential first-line therapy for metastatic renal cell cancer (RCC). The trial enrolled 50 patients with advanced RCC, demonstrating the triplet therapy's feasibility, tolerability, and encouraging activity. Key highlights include a 34% deep response rate and a 46% overall response rate, with the median...
10-17 14:00
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Barclays Initiates Coverage On Corvus Pharma with Overweight Rating, Announces Price Target of $16
Barclays analyst Etzer Darout initiates coverage on Corvus Pharma (NASDAQ:CRVS) with a Overweight rating and announces Price Target of $16.
10-13 20:04
Corvus Pharmaceuticals Appoints David Moore as Director
Corvus Pharmaceuticals ( ($CRVS) ) just unveiled an announcement. On October 2,...
10-03 04:56
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
Corvus Pharmaceuticals announced the appointment of David Moore to its Board of Directors. Moore, Executive Vice President at Novo Nordisk, brings 27 years of industry experience in strategy, commercial operations, and business development. His expertise, particularly in successful drug franchises like Ozempic and Wegovy, is expected to strengthen Corvus's ITK inhibitor platform for cancer and immune diseases. Moore expressed excitement about con...
10-02 20:01
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
